Diplomat Pharmacy, Inc. s in-depth stock price analysis indicates that the stock price has dropped -0.55% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -54.55% . Looking at the past 52 week period, the stock price is down -50.89% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Diplomat Pharmacy, Inc. has a negative value of -54.02 compared to overall market performance. Diplomat Pharmacy, Inc. (NYSE:DPLO) has tumbled 4.33% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 3.84% in the last four weeks. The stocks have underperformed the S&P 500 by 5.1% during the past week but Diplomat Pharmacy, Inc. (NYSE:DPLO) it has outperformed the index in 4 weeks by 1.98%.
Diplomat Pharmacy, Inc. (NYSE:DPLO) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.01 points or 0.07% at $14.6 with 1,323,728 shares getting traded. Post opening the session at $15.01, the shares hit an intraday low of $14.49 and an intraday high of $15.03 and the price was in this range throughout the day. The company has a market cap of $974 million and the number of outstanding shares has been calculated to be 66,730,998 shares. The 52-week high of Diplomat Pharmacy, Inc. (NYSE:DPLO) is $38.94 and the 52-week low is $12.25.
Diplomat Pharmacy Inc Last issued its quarterly earnings results on Nov 2, 2016. The company reported $0.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $0.24. The company had revenue of $1181.00 million for the quarter, compared to analysts expectations of $1258.11 million. The companys revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Diplomat Pharmacy Inc was Downgraded by Credit Suisse to Underperform on Nov 23, 2016.
Company has reported several Insider transactions to the SEC, on Sep 16, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 20,000 shares at 30.12 per share price.On Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at 33.60 per share price.On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at 35.08 per share price.
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.